YHP 1701

Drug Profile

YHP 1701

Alternative Names: YHP1701; YHR-1703/YHR-1704; YHR-1704/YHR-1703

Latest Information Update: 11 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yuhan
  • Class Antihyperlipidaemics; Antihypertensives
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Hyperlipidaemia; Hypertension

Most Recent Events

  • 10 Apr 2017 Yuhan Corporation plans a phase III trial for Hypertension and Hyperlipidaemia in unknown countries (NCT03103256)
  • 01 Apr 2017 Phase-III clinical trials in Hyperlipidaemia in South Korea (PO) (NCT03103256)
  • 01 Apr 2017 Phase-III clinical trials in Hypertension in South Korea (PO) (NCT03103256)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top